Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.
Germany's Protagen said it is rolling out its first diagnostic test kit for systemic sclerosis, a rheumatic disease in which autoimmune-induced inflammation, fibrosis and blood vessel disorders can harm a patient's organs and eventually cause death.
Biocept is bringing on a veteran GE Healthcare and Quest Diagnostics executive to guide the company's insurance reimbursement and medical contract strategy.
A company based in Northern Ireland is advancing a rapid blood test to screen for a heart attack, allowing for doctors to more quickly treat affected patients. Randox Health's low-cost diagnostic has shown promise in early testing.
A U.S. research team has made progress toward creating a biomarker blood test that can detect esophageal cancer on the early side, a major need in order to combat the lethal disease.
Researchers at Johns Hopkins are the latest group to take up the quest to find a biomarker that could screen for patients at high risk for suicide.
OncoCyte is vastly expanding testing of its urine-based bladder cancer diagnostic with the launch of a multisite clinical trial involving up to 1,200 patient samples.
A global team of researchers believe they've developed a blood test that could prevent neural tube birth defects such as spina bifida.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.